AGL 38.70 Increased By ▲ 1.13 (3.01%)
AIRLINK 130.60 Decreased By ▼ -1.90 (-1.43%)
BOP 5.65 Increased By ▲ 0.01 (0.18%)
CNERGY 3.83 Increased By ▲ 0.06 (1.59%)
DCL 8.70 Decreased By ▼ -0.17 (-1.92%)
DFML 42.15 Increased By ▲ 1.15 (2.8%)
DGKC 87.98 Decreased By ▼ -2.18 (-2.42%)
FCCL 34.92 Decreased By ▼ -0.16 (-0.46%)
FFBL 66.50 No Change ▼ 0.00 (0%)
FFL 10.56 Increased By ▲ 0.41 (4.04%)
HUBC 108.51 Increased By ▲ 2.11 (1.98%)
HUMNL 14.66 Increased By ▲ 1.26 (9.4%)
KEL 4.77 Decreased By ▼ -0.09 (-1.85%)
KOSM 6.98 Increased By ▲ 0.13 (1.9%)
MLCF 41.80 No Change ▼ 0.00 (0%)
NBP 59.75 Increased By ▲ 1.17 (2%)
OGDC 183.40 Increased By ▲ 2.15 (1.19%)
PAEL 26.25 Increased By ▲ 0.55 (2.14%)
PIBTL 5.91 Increased By ▲ 0.08 (1.37%)
PPL 146.50 Decreased By ▼ -1.90 (-1.28%)
PRL 23.54 Increased By ▲ 0.32 (1.38%)
PTC 16.30 Increased By ▲ 1.06 (6.96%)
SEARL 68.55 Decreased By ▼ -0.24 (-0.35%)
TELE 7.22 Decreased By ▼ -0.02 (-0.28%)
TOMCL 35.81 Decreased By ▼ -0.19 (-0.53%)
TPLP 7.70 Increased By ▲ 0.30 (4.05%)
TREET 14.20 Decreased By ▼ -0.04 (-0.28%)
TRG 50.35 Decreased By ▼ -0.50 (-0.98%)
UNITY 26.75 Increased By ▲ 0.35 (1.33%)
WTL 1.21 No Change ▼ 0.00 (0%)
BR100 9,797 Increased By 29.7 (0.3%)
BR30 29,643 Increased By 243 (0.83%)
KSE100 92,336 Increased By 397.9 (0.43%)
KSE30 28,834 Increased By 89.9 (0.31%)

Searle Company Limited (SEARL) has earned approval from the Drug Regulatory Authority of Pakistan (DRAP) for ADALIMUMAB, the first locally manufactured Monoclonal antibody (mABs) in Pakistan.

The company announced the development in its notice to the Pakistan Stock Exchange (PSX) on Thursday.

“We are pleased to share that SEARL has received approval from the DRAP for ADALIMUMAB, a biosimilar drug developed in collaboration with BioRay Biopharmaceuticals Co. Limited, China, this marks the first locally manufactured Monoclonal antibody (mABs) in Pakistan,” read the notice.

It is pertinent to inform that mABs are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, modify or mimic the immune system’s attack on cells that are not wanted, such as cancer cells.

“The introduction of ADALIMUMAB to the market within the next 3-6 months is a strategic move aimed at providing high-quality, affordable biotechnology medicines to patients in Pakistan,” the pharmaceutical company shared.

“This development aligns with our commitment to diversifying our product portfolio, thereby enhancing the quality of earnings and shareholders’ value,” it added.

Earlier in September, SEARL announced that it has earned approval from the UAE ministry, and registered its manufacturing facility in the Middle Eastern country.

The company back then informed that it was expanding rapidly in several regions of the world including South Asia, Southeast Asia, Africa, Francophone Africa, GCC, Commonwealth of Independent States (CIS), Canada, Europe and Latin America (EU&LATAM) etc.

Comments

Comments are closed.

Az_Iz Dec 14, 2023 05:35pm
Good to see advancement in technology.
thumb_up Recommended (0)
Ahsanullah Dec 15, 2023 01:18am
Assalamualaikum I m Ahsan manya here i want to say you . Tarif krny walo ki kami hojae but jalny walo ki kami nh honi chaiye . Regard Ahsan manya
thumb_up Recommended (0)
Waseem Shahzad Dec 15, 2023 08:06am
This company's products is very quality products it's quality know all over the Pakistan specially Searle medicine very effectively known some products are known each one of them 1. Hydrallin 2. Nuberol 3. Extors very effective products
thumb_up Recommended (0)
Muhammad Bilal Dec 15, 2023 06:08pm
Feeling Proud to be a part of Searle Pharmaceuticals as a Regional Manager Oncology North 2 Peshawar
thumb_up Recommended (0)
Dr. Dj Dec 15, 2023 06:59pm
Welldone good but why Draps policies made multinationals Giants to leave atleast 10 of them left pak like Roche ,Merck to Novartis etc which leads to reduction in allot number of medicines in all fields specially oncology and Pyschaitry etc instead we would invited more make easier so RnD raw materials manufacturing making of new molecules trials research biotechnology advancement vaccine plants development of new market for world like china India but instead our curropt elite whom I know personally work under them as pharmacist took DRAP and hijacked it and made those pharma giants to leave rather expanding and inviting more would have helped economy allot also wide range of meds etc with cost effective but this is very late small
thumb_up Recommended (0)